
Denmark-based biotech company Forward Pharma, which is developing a biological drug to treat moderat-to-severe psoriasis, believes that the company’s candidate has a better profile than most of the drugs currently on the market.
The market for psoriasis treatments, which has been focused on ointments for many years, is betting big on biologics now with injectable and oral drugs. Forward Pharma’s candidate is an oral drug with the preliminary name FP187.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app